A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH‐binding activity by abolishing receptor homodimerization.
Authors:
Open Access
- 1 March 1994
- journal article
- research article
- Published by Springer Nature in The EMBO Journal
- Vol. 13 (6) , 1386-1395
Abstract
Growth hormone (GH) elicits a variety of biological activities mainly mediated by the GH receptor (GHR), a transmembrane protein that, based on in vitro studies, seemed to function as a homodimer. To test this hypothesis directly, we investigated patients displaying the classic features of Laron syndrome (familial GH resistance characterized by severe dwarfism and metabolic dysfunction), except for the presence of normal binding activity of the plasma GH‐binding protein, a molecule that derives from the exoplasmic‐coding domain of the GHR gene. In two unrelated families, the same GHR mutation was identified, resulting in the substitution of a highly conserved aspartate residue by histidine at position 152 (D152H) of the exoplasmic domain, within the postulated interface sequence involved in homodimerization. The recombinant mutated receptor protein was correctly expressed at the plasma membrane. It displayed subnormal GH‐binding activity, a finding in agreement with the X‐ray crystal structure data inferring this aspartate residue outside the GH‐binding domain. However, mAb‐based studies suggested the critical role of aspartate 152 in the proper folding of the interface area. We show that a recombinant soluble form of the mutant receptor is unable to dimerize, the D152H substitution also preventing the formation of heterodimers of wild‐type and mutant molecules. These results provide in vivo evidence that monomeric receptors are inactive and that receptor dimerization is involved in the primary signalling of the GH‐associated growth‐promoting and metabolic actions.Keywords
This publication has 45 references indexed in Scilit:
- Laron‐type dwarfism with apparently normal high affinity serum growth hormone‐binding proteinClinical Endocrinology, 1991
- Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism.Journal of Clinical Investigation, 1991
- Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamilyCell, 1990
- Laron Dwarfism and Mutations of the Growth Hormone–Receptor GeneNew England Journal of Medicine, 1989
- High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning MutagenesisScience, 1989
- A Newly Defined Property of Somatotropin: Priming of Macrophages for Production of Superoxide AnionScience, 1988
- Growth hormone receptor and serum binding protein: purification, cloning and expressionNature, 1987
- The Nature and Regulation of the Receptors for Pituitary Growth HormoneAnnual Review of Physiology, 1985
- The protein data bank: A computer-based archival file for macromolecular structuresJournal of Molecular Biology, 1977
- Laron's dwarfism: Studies on the nature of the defectThe Journal of Pediatrics, 1973